A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine (UROGESIC BLUE)

First FDA approval2010-11-19
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$4.01/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$4.01
Across all dosage forms in distribution.
Highest NADAC
$4.01
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine used for?

Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine is a this drug class medication tracked in Medicare Part D.

Is there a generic for Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine?

No. Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine is brand-only with no generic equivalents currently in market.

How much does my plan pay for Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine?

Across 329 Part D plans, Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine averages $4.01/unit (NADAC). Lowest available: $4.01/unit. Highest in distribution: $4.01/unit.

Is Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine on the FDA shortage list?

No. Methenamine, Sodium Phosphate, Monobasic, Methylene Blue, and Hyoscyamine is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.